Clinical trials: Cancer of Brain and Nervous System
Brain Tumor, Surgery
Effect of Propofol-Dexmedetomidine on Cerebral Oxygenation and Metabolism During Brain Tumor Resection
Despite theoretical benefits of intravenous agents, volatile agents remain popular. In a study comparing desflurane, isoflurane, and sevoflurane in a porcine model of intracranial hypertension, at equipotent doses and…
- Trial name
- NCT02575521
- Testing
- Propofol-Dexmedetomidine group, Sevoflurane group
- Volunteers
- 50 people
- Sponsor
- Mansoura University
Brain and Central Nervous System Tumors
Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide
Bortezomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing…
- Trial name
- NCT00990652
- Testing
- Bortezomib, Temozolomide
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Northwestern University
Brain Edema, Brain Tumor
Tolerability Study of Xerecept® in Pediatric Patients
This study is being conducted to evaluate the safety and tolerability of Xerecept® in children with central nervous system tumors and to identify appropriate doses of Xerecept® to be used in subsequent pediatric clinical trials.
- Trial name
- NCT01369121
- Testing
- XERECEPT
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Celtic Pharma Development Services
Advanced Cancer, Brain Involvement
Study of 4-Demethylcholesteryloxycarbonylpenclomedine (DM-CHOC-PEN) in Patients With Advanced Cancer
DM-CHOC-PEN is a polychlorinated pyridine cholesteryl carbonate that has demonstrated antineoplastic activities in human xenograft intracerebrally implanted tumor mouse models, acceptable preclinical toxicities in mouse, rat and…
- Trial name
- DM-CHOC-PEN (NCT01048008)
- Testing
- DM-CHOC-PEN
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- DEKK-TEC, Inc.
Brain Stem Neoplasm, Pineal Region Neoplasm
Entinostat in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors
This phase I trial studies the side effects and best dose of entinostat in treating pediatric patients with solid tumors that have come back or have not responded to treatment.
- Conditions
- Brain Stem Neoplasm, Pineal Region Neoplasm, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm
- Trial name
- NCT02780804
- Testing
- Entinostat, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 21 sites in United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Head and Neck Cancer, Skull Base--Cancer
HRQoL in Patients With Solid Tumors Treated With Hadrontherapy
The Quality of Life of patients treated with hadrontherapy is still limited. Two cohorts are established, they will be receiving specific standardized questionnaires to be evalutaed in their results.
- Conditions
- Head and Neck Cancer, Skull Base--Cancer, Brain Cancer
- Trial name
- HadroQoL (NCT05947149)
- Testing
- questionnaires administration
- Where
- Italy
- Volunteers
- 180 people
- Sponsor
- CNAO National Center of Oncological Hadrontherapy
Adult Central Nervous System Germ Cell Tumor, Adult Malignant Meningioma
Stereotactic Radiosurgery in Treating Patients With Brain Tumors
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. PURPOSE: Phase I trial to study the effectiveness of stereotactic radiosurgery in treating patients who have brain tumors.
- Conditions
- Adult Central Nervous System Germ Cell Tumor, Adult Malignant Meningioma, Adult Medulloblastoma, Adult Noninfiltrating Astrocytoma
- Trial name
- NCT00019578
- Testing
- Sterotactic radiosurgery
- Where
- United States
- Sponsor
- National Institutes of Health Clinical Center (CC)
Brain and Central Nervous System Tumors
Immunotoxin Therapy in Treating Children With Recurrent Malignant Gliomas
RATIONALE: Immunotoxins can locate tumor cells and kill them without harming normal cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of immunotoxin therapy and to see how well it works in treating…
- Trial name
- NCT00053040
- Testing
- cintredekin besudotox, conventional surgery
- Sponsor
- Pediatric Brain Tumor Consortium
Amyloidosis
Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis
The drugs dexamethasone and bortezomib are both FDA-approved for the treatment of multiple myeloma, a disease very similar to amyloidosis. However, they are currently investigational for the treatment of amyloidosis.
- Trial name
- NCT01083316
- Testing
- Bortezomib, Dexamethasone, Melphalan
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Boston Medical Center
Cushing's Disease, Hypercortisolism
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress.
- Conditions
- Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
- Trial name
- OPTIMAL (NCT06701838)
- Testing
- 11C-Methionine PET/CT
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Brain Tumors, Central Nervous System Tumors
Combination Chemotherapy Plus Radiation Therapy in Treating Children With Newly Diagnosed Brain Stem Glioma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003935
- Testing
- etoposide, vincristine sulfate, radiation therapy
- Where
- 110 sites in United States, Australia and 4 more
- Volunteers
- 31 people
- Sponsor
- Children's Oncology Group
Glioblastoma, Brain Neoplasms
NovoTTF Therapy in Treating Patients With Recurrent Glioblastoma Multiforme
This pilot phase II trial studies how well Novocure's Tumor Treating Electric Fields (NovoTTF) therapy works in treating patients with recurrent glioblastoma multiforme.
- Trial name
- NCT01954576
- Testing
- NovoTTF-100A, Quality-of-life assessment, Laboratory biomarker analysis
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- University of Florida
Hyperprolactinemia, Prolactinoma
Treatment of Hyperprolactinemia With the Non-ergoline Dopamine Agonist Ropinirole
The purpose of this study is to evaluate the use of the non-ergoline dopamine agonist ropinirole for the treatment of hyperprolactinemia in patients with idiopathic hyperprolactinemia and prolactinomas.
- Trial name
- NCT03038308
- Testing
- Ropinirole
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Columbia University
Brain Cancer
Safety Study of Afatinib for Brain Cancer
The purpose of this study is to try to determine the maximum safe dose of afatinib that can be administered to people with brain cancer.
- Trial name
- NCT02423525
- Testing
- Afatinib
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Santosh Kesari
Brain and Central Nervous System Tumors
Brachytherapy in Treating Patients With Recurrent Malignant Glioma
RATIONALE: Brachytherapy uses radioactive material to kill cancer cells remaining after surgery. PURPOSE: Phase I trial to study the effectiveness of brachytherapy in treating patients who have recurrent malignant glioma.
- Trial name
- NCT00045474
- Testing
- adjuvant therapy, iodine I 125
- Where
- 9 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma
Whole Brain Radiotherapy Following Local Treatment of Intracranial Metastases of Melanoma
People with brain metastases from melanoma are offered different treatment options after local treatment of their brain metastases via surgery or stereotactic irradiation.
- Trial name
- WBRTMel (NCT01503827)
- Testing
- WBRT
- Where
- 23 sites in Australia, Norway and 1 more
- Volunteers
- 220 people
- Sponsor
- Melanoma and Skin Cancer Trials Limited
Lymphoma, Solid Malignancy
PET Imaging of Subjects Using 124I-PU-AD
This is a first in-human, open-label pilot (microdose) study of the positron-emitting agent 124I-PU-AD in subjects with specific cancer types (solid malignancy, lymphoma, and/or myeloma) and/or Alzheimer's disease.
- Conditions
- Lymphoma, Solid Malignancy, Alzheimer Disease, Myeloma
- Trial name
- NCT03371420
- Testing
- PU-AD, PET Scan, Blood Draws
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Samus Therapeutics, Inc.
Non-Small Cell Lung Cancer, Brain Metastases
Safety Study of Radiotherapy and Concurrent Erlotinib (Tarceva®) for Brain Metastases From a Non-Small Cell Lung Cancer
Lung cancer is a leading cause of death worldwide. Brain metastases manifest as the first site of disease failure in between 15-30% of patients with non-small cell lung cancer (NSCLC).
- Trial name
- NCT00536861
- Testing
- erlotinib
- Where
- Netherlands
- Volunteers
- 11 people
- Sponsor
- Amsterdam UMC, location VUmc
Glioblastoma Multiforme
Radiation Boost for Newly Diagnosed Glioblastoma Multiforme
The purpose of this study is to determine treatment related toxicity, tumor response, progression-free survival and quality of life of newly diagnosed Glioblastoma Multiforme (GBM) patients undergoing a combination of surgical…
- Trial name
- NCT00376103
- Testing
- temozolomide, Brachytherapy, External Beam Radiation Therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Methodist Healthcare - Memphis
Glioblastoma
Capecitabine + Bevacizumab in Patients With Recurrent Glioblastoma
This study involves participants with recurrent glioblastoma brain tumors (GBM). This means that a participant's brain tumor has either returned after being treated by a previous therapy, or has continued to progress despite…
- Trial name
- NCT02669173
- Testing
- Capecitabine, Bevacizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Case Comprehensive Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.